We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
- Authors
Puliafito, Ivana; Chillari, Federico; Russo, Alessandro; Cantale, Ornella; Sciacca, Dorotea; Castorina, Luigi; Colarossi, Cristina; Franchina, Tindara; Vitale, Maria Paola; Ricciardi, Giuseppina Rosaria Rita; Adamo, Vincenzo; Esposito, Francesca; Giuffrida, Dario
- Abstract
Background: Lung neuroendocrine neoplasms (NENs) are rare malignancies developed from bronchial mucosa. Because of its rarity and complex histopathology, there is limited data on the role of chemotherapy in this subset of tumors. Few studies regarding the treatment of poorly differentiated lung NENs, known as neuroendocrine carcinomas (NECs), are available and many limits are detectable as heterogeneity of tumor samples including different origins and different clinical behaviors, moreover, no evidence of therapeutic advances have been achieved along the last thirty years. Method: We performed a retrospective analysis of 70 patients affected by poorly differentiated lung NECs: half of patients underwent a first line therapy with a combination of cisplatin plus etoposide; the remaining patients receiving carboplatin instead of cisplatin, plus etoposide. Results: In our analysis, the outcomes of patients treated with either cisplatin or carboplatin schedule are similar in terms of ORR (44% versus 33%), DCR (75% versus 70%), PFS (6.0 versus 5.0 months) and OS (13.0 versus 10 months). Median number of chemotherapy cycles was 4 (range 1-8). The 18% of patients required a dose reduction. Main toxicities reported were hematological (70.5%), gastrointestinal (26.5%) and fatigue (18%). Conclusion: Survival rate in our study suggests that high grade lung NENs are characterized by an aggressive behavior and a poor prognosis, despite the treatment with platinum/etoposide according to available data. Clinical results of present study contribute to strengthen available data on the usefulness of platinum/etoposide regimen in the treatment of poorly differentiated lung NENs.
- Subjects
NEUROENDOCRINE tumors; TREATMENT effectiveness; ETOPOSIDE; PLATINUM; LUNGS; THYROID cancer
- Publication
Frontiers in Endocrinology, 2023, Vol 14, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2023.1065599